{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T23:25:18Z","timestamp":1776295518247,"version":"3.50.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,11,9]],"date-time":"2021-11-09T00:00:00Z","timestamp":1636416000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,11,9]],"date-time":"2021-11-09T00:00:00Z","timestamp":1636416000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100007827","name":"American College of Gastroenterology","doi-asserted-by":"crossref","award":["Pilot Research Award"],"award-info":[{"award-number":["Pilot Research Award"]}],"id":[{"id":"10.13039\/100007827","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Patient"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1007\/s40271-021-00561-9","type":"journal-article","created":{"date-parts":[[2021,11,9]],"date-time":"2021-11-09T02:02:21Z","timestamp":1636423341000},"page":"353-365","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Women\u2019s Willingness to Accept Risks of Medication for Inflammatory Bowel Disease During Pregnancy"],"prefix":"10.1007","volume":"15","author":[{"given":"Tatyana","family":"Kushner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelyn","family":"Fairchild","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F. Reed","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruce E.","family":"Sands","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uma","family":"Mahadevan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sreedhar","family":"Subramanian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashwin","family":"Ananthakrishnan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina","family":"Ha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6489-7043","authenticated-orcid":false,"given":"Meenakshi","family":"Bewtra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,11,9]]},"reference":[{"key":"561_CR1","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.15585\/mmwr.mm6542a3","volume":"65","author":"JM Dahlhamer","year":"2016","unstructured":"Dahlhamer JM, Zammitti EP, Ward BW, et al. Prevalence of inflammatory bowel disease among adults aged >\/=18 years-United States, 2015. MMWR Morb Mortal Wkly Rep. 2016;65:1166\u20139.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"561_CR2","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/j.pop.2017.07.010","volume":"44","author":"T Sairenji","year":"2017","unstructured":"Sairenji T, Collins KL, Evans DV. An update on inflammatory bowel disease. Prim Care. 2017;44:673\u201392.","journal-title":"Prim Care"},{"key":"561_CR3","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1136\/gut.21.6.469","volume":"21","author":"CP Willoughby","year":"1980","unstructured":"Willoughby CP, Truelove SC. Ulcerative colitis and pregnancy. Gut. 1980;21:469\u201374.","journal-title":"Gut"},{"key":"561_CR4","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1136\/gut.25.1.52","volume":"25","author":"R Khosla","year":"1984","unstructured":"Khosla R, Willoughby CP, Jewell DP. Crohn\u2019s disease and pregnancy. Gut. 1984;25:52\u20136.","journal-title":"Gut"},{"key":"561_CR5","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1038\/ajg.2016.254","volume":"111","author":"A de Lima-Karagiannis","year":"2016","unstructured":"de Lima-Karagiannis A, Zelinkova-Detkova Z, van der Woude CJ. The effects of active IBD during pregnancy in the era of novel IBD therapies. Am J Gastroenterol. 2016;111:1305\u201312.","journal-title":"Am J Gastroenterol"},{"key":"561_CR6","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.cgh.2012.10.024","volume":"11","author":"Z Zelinkova","year":"2013","unstructured":"Zelinkova Z, van der Ent C, Bruin KF, et al. Effects of discontinuing anti-tumor necrosis factor therapy during pregnancy on the course of inflammatory bowel disease and neonatal exposure. Clin Gastroenterol Hepatol. 2013;11:318\u201321.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"561_CR7","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1038\/s41395-018-0176-7","volume":"113","author":"M Luu","year":"2018","unstructured":"Luu M, Benzenine E, Doret M, et al. Continuous anti-TNFalpha use throughout pregnancy: possible complications for the mother but not for the fetus. A retrospective cohort on the French National Health Insurance Database (EVASION). Am J Gastroenterol. 2018;113:1669\u201377.","journal-title":"Am J Gastroenterol"},{"key":"561_CR8","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1177\/0960327114550882","volume":"34","author":"S Mozaffari","year":"2015","unstructured":"Mozaffari S, Abdolghaffari AH, Nikfar S, et al. Pregnancy outcomes in women with inflammatory bowel disease following exposure to thiopurines and antitumor necrosis factor drugs: a systematic review with meta-analysis. Hum Exp Toxicol. 2015;34:445\u201359.","journal-title":"Hum Exp Toxicol"},{"key":"561_CR9","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1053\/j.gastro.2006.04.049","volume":"131","author":"U Mahadevan","year":"2006","unstructured":"Mahadevan U, Kane S. American gastroenterological association institute technical review on the use of gastrointestinal medications in pregnancy. Gastroenterology. 2006;131:283\u2013311.","journal-title":"Gastroenterology"},{"key":"561_CR10","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1093\/ibd\/izz037","volume":"25","author":"U Mahadevan","year":"2019","unstructured":"Mahadevan U, Robinson C, Bernasko N, et al. Inflammatory bowel disease in pregnancy clinical care pathway: a report from the american gastroenterological association IBD Parenthood Project Working Group. Inflamm Bowel Dis. 2019;25:627\u201341.","journal-title":"Inflamm Bowel Dis"},{"key":"561_CR11","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1002\/ibd.22948","volume":"19","author":"M Akbari","year":"2013","unstructured":"Akbari M, Shah S, Velayos FS, et al. Systematic review and meta-analysis on the effects of thiopurines on birth outcomes from female and male patients with inflammatory bowel disease. Inflamm Bowel Dis. 2013;19:15\u201322.","journal-title":"Inflamm Bowel Dis"},{"key":"561_CR12","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1053\/j.gastro.2020.11.038","volume":"160","author":"U Mahadevan","year":"2021","unstructured":"Mahadevan U, Long MD, Kane SV, et al. Pregnancy and neonatal outcomes after fetal exposure to biologics and thiopurines among women with inflammatory bowel disease. Gastroenterology. 2021;160:1131\u20139.","journal-title":"Gastroenterology"},{"key":"561_CR13","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1111\/aogs.13570","volume":"98","author":"E Wolgast","year":"2019","unstructured":"Wolgast E, Lindh-Astrand L, Lilliecreutz C. Women\u2019s perceptions of medication use during pregnancy and breastfeeding\u2014a Swedish cross-sectional questionnaire study. Acta Obstet Gynecol Scand. 2019;98:856\u201364.","journal-title":"Acta Obstet Gynecol Scand"},{"key":"561_CR14","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.crohns.2009.10.001","volume":"4","author":"RE Mountifield","year":"2010","unstructured":"Mountifield RE, Prosser R, Bampton P, et al. Pregnancy and IBD treatment: this challenging interplay from a patients\u2019 perspective. J Crohns Colitis. 2010;4:176\u201382.","journal-title":"J Crohns Colitis"},{"key":"561_CR15","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1038\/ajg.2015.321","volume":"110","author":"M Bewtra","year":"2015","unstructured":"Bewtra M, Fairchild AO, Gilroy E, et al. Inflammatory bowel disease patients\u2019 willingness to accept medication risk to avoid future disease relapse. Am J Gastroenterol. 2015;110:1675\u201381.","journal-title":"Am J Gastroenterol"},{"key":"561_CR16","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1097\/01.MIB.0000437498.14804.50","volume":"20","author":"M Bewtra","year":"2014","unstructured":"Bewtra M, Kilambi V, Fairchild AO, et al. Patient preferences for surgical versus medical therapy for ulcerative colitis. Inflamm Bowel Dis. 2014;20:103\u201314.","journal-title":"Inflamm Bowel Dis"},{"key":"561_CR17","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1111\/j.1365-2036.2012.05130.x","volume":"36","author":"CP Selinger","year":"2012","unstructured":"Selinger CP, Eaden J, Selby W, et al. Patients\u2019 knowledge of pregnancy-related issues in inflammatory bowel disease and validation of a novel assessment tool ('CCPKnow\u2019). Aliment Pharmacol Ther. 2012;36:57\u201363.","journal-title":"Aliment Pharmacol Ther"},{"key":"561_CR18","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.jval.2010.11.013","volume":"14","author":"JF Bridges","year":"2011","unstructured":"Bridges JF, Hauber AB, Marshall D, et al. Conjoint analysis applications in health\u2014a checklist: a report of the ISPOR Good Research Practices for Conjoint Analysis Task Force. Value Health. 2011;14:403\u201313.","journal-title":"Value Health"},{"key":"561_CR19","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1093\/ecco-jcc\/jjw052","volume":"10","author":"ZR Gallinger","year":"2016","unstructured":"Gallinger ZR, Rumman A, Nguyen GC. Perceptions and attitudes towards medication adherence during pregnancy in inflammatory bowel disease. J Crohns Colitis. 2016;10:892\u20137.","journal-title":"J Crohns Colitis"},{"key":"561_CR20","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1007\/s11894-009-0059-6","volume":"11","author":"M Moscandrew","year":"2009","unstructured":"Moscandrew M, Kane S. Inflammatory bowel diseases and management considerations: fertility and pregnancy. Curr Gastroenterol Rep. 2009;11:395\u20139.","journal-title":"Curr Gastroenterol Rep"},{"key":"561_CR21","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1111\/j.1539-6924.2008.01137.x","volume":"29","author":"VH Visschers","year":"2009","unstructured":"Visschers VH, Meertens RM, Passchier WW, et al. Probability information in risk communication: a review of the research literature. Risk Anal. 2009;29:267\u201387.","journal-title":"Risk Anal"},{"key":"561_CR22","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1509\/jmkr.39.2.214.19080","volume":"39","author":"BJ Kanninen","year":"2002","unstructured":"Kanninen BJ. Optimal design for multinomial choice experiments. J Mark Res. 2002;39:214\u201327.","journal-title":"J Mark Res"},{"key":"561_CR23","unstructured":"Kuhfeld WF. Experimental design: efficiency, coding, and choice designs. MR-2010C. 2010."},{"key":"561_CR24","unstructured":"Kuhfeld WF. Marketing research methods in SAS. MR-2010. 2010."},{"key":"561_CR25","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1177\/002224379603300305","volume":"33","author":"J Huber","year":"1996","unstructured":"Huber J, Zwerina K. The Importance of utility Balance and Efficient Choice Designs. J Mark Res. 1996;33:307\u201317.","journal-title":"J Mark Res"},{"key":"561_CR26","unstructured":"Dey A. Orthogonal fractional factorial designs 133. Wiley; 1985."},{"key":"561_CR27","doi-asserted-by":"publisher","first-page":"S90","DOI":"10.1016\/j.amepre.2007.03.008","volume":"32","author":"DA Dillman","year":"2007","unstructured":"Dillman DA, Smyth JD. Design effects in the transition to web-based surveys. Am J Prev Med. 2007;32:S90\u20136.","journal-title":"Am J Prev Med"},{"key":"561_CR28","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.jval.2018.07.876","volume":"22","author":"FR Johnson","year":"2019","unstructured":"Johnson FR, Yang JC, Reed SD. The internal validity of discrete choice experiment data: a testing tool for quantitative assessments. Value Health. 2019;22:157\u201360.","journal-title":"Value Health"},{"key":"561_CR29","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1080\/14737167.2017.1389648","volume":"17","author":"EM Janssen","year":"2017","unstructured":"Janssen EM, Marshall DA, Hauber AB, et al. Improving the quality of discrete-choice experiments in health: how can we assess validity and reliability? Expert Rev Pharmacoecon Outcomes Res. 2017;17:531\u201342.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"561_CR30","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1016\/j.jval.2018.04.1822","volume":"21","author":"T Tervonen","year":"2018","unstructured":"Tervonen T, Schmidt-Ott T, Marsh K, et al. Assessing rationality in discrete choice experiments in health: an investigation into the use of dominance tests. Value Health. 2018;21:1192\u20137.","journal-title":"Value Health"},{"key":"561_CR31","doi-asserted-by":"publisher","first-page":"196","DOI":"10.3109\/00365521.2015.1079924","volume":"51","author":"M Bortlik","year":"2016","unstructured":"Bortlik M, Duricova D, Machkova N, et al. Discontinuation of anti-tumor necrosis factor therapy in inflammatory bowel disease patients: a prospective observation. Scand J Gastroenterol. 2016;51:196\u2013202.","journal-title":"Scand J Gastroenterol"},{"key":"561_CR32","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1177\/1753495X20919214","volume":"14","author":"RH Cao","year":"2021","unstructured":"Cao RH, Grimm MC. Pregnancy and medications in inflammatory bowel disease. Obstet Med. 2021;14:4\u201311.","journal-title":"Obstet Med"},{"key":"561_CR33","unstructured":"https:\/\/www.cdc.gov\/reproductivehealth\/maternalinfanthealth\/pretermbirth.htm. Accessed 13 Aug 2021."},{"key":"561_CR34","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.gtc.2016.02.006","volume":"45","author":"RA McConnell","year":"2016","unstructured":"McConnell RA, Mahadevan U. Pregnancy and the patient with inflammatory bowel disease: fertility, treatment, delivery, and complications. Gastroenterol Clin N Am. 2016;45:285\u2013301.","journal-title":"Gastroenterol Clin N Am"},{"key":"561_CR35","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1002\/ibd.21369","volume":"17","author":"O Stephansson","year":"2011","unstructured":"Stephansson O, Larsson H, Pedersen L, et al. Congenital abnormalities and other birth outcomes in children born to women with ulcerative colitis in Denmark and Sweden. Inflamm Bowel Dis. 2011;17:795\u2013801.","journal-title":"Inflamm Bowel Dis"},{"key":"561_CR36","doi-asserted-by":"publisher","first-page":"2750","DOI":"10.1007\/s10620-015-3677-x","volume":"60","author":"A O'Toole","year":"2015","unstructured":"O\u2019Toole A, Nwanne O, Tomlinson T. Inflammatory bowel disease increases risk of adverse pregnancy outcomes: a meta-analysis. Dig Dis Sci. 2015;60:2750\u201361.","journal-title":"Dig Dis Sci"},{"key":"561_CR37","first-page":"1091","volume":"20","author":"G Broms","year":"2014","unstructured":"Broms G, Granath F, Linder M, et al. Birth outcomes in women with inflammatory bowel disease: effects of disease activity and drug exposure. Inflamm Bowel Dis. 2014;20:1091\u20138.","journal-title":"Inflamm Bowel Dis"},{"key":"561_CR38","doi-asserted-by":"publisher","first-page":"1846","DOI":"10.1002\/ibd.21583","volume":"17","author":"F Schnitzler","year":"2011","unstructured":"Schnitzler F, Fidder H, Ferrante M, et al. Outcome of pregnancy in women with inflammatory bowel disease treated with antitumor necrosis factor therapy. Inflamm Bowel Dis. 2011;17:1846\u201354.","journal-title":"Inflamm Bowel Dis"},{"key":"561_CR39","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1111\/j.1572-0241.2004.30186.x","volume":"99","author":"JA Katz","year":"2004","unstructured":"Katz JA, Antoni C, Keenan GF, et al. Outcome of pregnancy in women receiving infliximab for the treatment of Crohn\u2019s disease and rheumatoid arthritis. Am J Gastroenterol. 2004;99:2385\u201392.","journal-title":"Am J Gastroenterol"},{"key":"561_CR40","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1053\/j.gastro.2018.05.040","volume":"155","author":"R Matro","year":"2018","unstructured":"Matro R, Martin CF, Wolf D, et al. Exposure concentrations of infants breastfed by women receiving biologic therapies for inflammatory bowel diseases and effects of breastfeeding on infections and development. Gastroenterology. 2018;155:696\u2013704.","journal-title":"Gastroenterology"},{"key":"561_CR41","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1016\/j.cgh.2016.03.018","volume":"14","author":"A de Lima","year":"2016","unstructured":"de Lima A, Zelinkova Z, Mulders AG, et al. Preconception care reduces relapse of inflammatory bowel disease during pregnancy. Clin Gastroenterol Hepatol. 2016;14:1285-1292 e1.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"561_CR42","unstructured":"https:\/\/ibdparenthoodproject.gastro.org\/."},{"key":"561_CR43","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1093\/ibd\/izy280","volume":"25","author":"J Reich","year":"2019","unstructured":"Reich J, Guo L, Groshek J, et al. Social media use and preferences in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2019;25:587\u201391.","journal-title":"Inflamm Bowel Dis"},{"key":"561_CR44","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1097\/MIB.0000000000001110","volume":"23","author":"B Martinez","year":"2017","unstructured":"Martinez B, Dailey F, Almario CV, et al. Patient understanding of the risks and benefits of biologic therapies in inflammatory bowel disease: insights from a large-scale analysis of social media platforms. Inflamm Bowel Dis. 2017;23:1057\u201364.","journal-title":"Inflamm Bowel Dis"}],"container-title":["The Patient - Patient-Centered Outcomes Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40271-021-00561-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40271-021-00561-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40271-021-00561-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,11]],"date-time":"2022-05-11T15:33:45Z","timestamp":1652283225000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40271-021-00561-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,9]]},"references-count":44,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["561"],"URL":"https:\/\/doi.org\/10.1007\/s40271-021-00561-9","relation":{},"ISSN":["1178-1653","1178-1661"],"issn-type":[{"value":"1178-1653","type":"print"},{"value":"1178-1661","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,9]]},"assertion":[{"value":"18 October 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Kushner received an American College of Gastroenterology Pilot Research Award to support this project.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"TK has participated in an advisory board for Gilead. BS has received consulting fees from 4D Pharma, AbbVie, Allergan, Amgen, Arena Pharmaceuticals, AstraZeneca, Boehringer Ingelheim, Boston Pharmaceuticals, Capella Biosciences, Celgene, Celltrion Healthcare, enGene, Ferring, Genentech, Gilead, Hoffmann-La Roche, Immunic, Ironwood Pharmaceuticals, Janssen, Lilly, Lyndra, MedImmune, Morphic Therapeutic, Oppilan Pharma, OSE Immunotherapeutics, Otsuka, Palatin Technologies, Pfizer, Progenity, Prometheus Laboratories, Redhill Biopharma, Rheos Medicines, Seres Therapeutics, Shire, Synergy Pharmaceuticals, Takeda, Target PharmaSolutions, Theravance Biopharma R&D, TiGenix, and Vivelix Pharmaceuticals; honoraria for speaking in continuing medical education (CME) programs from Takeda, Janssen, Lilly, Gilead, Pfizer, and Genentech; and research funding from Celgene, Pfizer, Takeda, Theravance Biopharma R&D, and Janssen. UM has received consulting fees from Janssen, AbbVie, Takeda, Gilead, and Bristol Myers Squibb and research funding from Pfizer, Celgene, and Genentech. SS has received speaker fees from Merck Sharpe & Dohme, AbbVie, Dr. Falk Pharmaceuticals, Takeda, and Janssen and educational grants from Takeda and Janssen. AA has received consulting fees from Kyn Therapeutics and Sun Pharma. CH has received advisory\/consultant fees from AbbVie, Galen Atlantica, Genentech, Janssen, Pfizer, Salix, and Takeda; grant support from Pfizer; and honoraria for speaking from AbbVie, Medical Education Network, Prova Education, Vindico, and Imedex. MB has received research funding from Janssen, GlaxoSmithKline, and Takeda; has served as a consultant for Janssen, AbbVie, Bristol Myers Squibb, and Pfizer; and has received honorarium for participation in a CME program sponsored by AbbVie. AF has received salary or subcontractor research support fees supported in part by research funding from AbbVie, Janssen, Pfizer, Grifols, GlaxoSmithKline, Genentech, Lilly, and Amgen. FRJ has made available online a detailed listing of financial disclosures: .","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The <b>s<\/b>urvey is provided in the ESM. Data are available upon request.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"The study and final survey instrument were approved by all participating institutions. Ethics approval was obtained at each institution under each institutional review board under expedited procedure.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"AF assisted with the conduct of the study and designing the statistical analysis, performed data analysis, interpreted the data, and edited the manuscript. TK assisted with the research protocol and the conduct of the study, interpreted the data, and edited the manuscript. FRJ assisted with the research protocol, the conduct of the study, and designing the statistical analysis; performed data analysis; interpreted the data; and edited the manuscript. BS assisted with the research protocol, planning the study, and interpretation of data, and edited the manuscript. UM assisted with planning the study and edited the manuscript. SS assisted with the study design, the research protocol, interpretation of data, and manuscript editing. AA assisted with data collection and edited the manuscript. CH assisted with data collection and edited the manuscript. MB assisted with writing the research protocol and the planning and conduct of the study, assisted in data analysis, interpreted the data, and drafted the manuscript. She is the guarantor and affirms that the manuscript is an honest, accurate, and transparent account of the study being reported.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"All potential participants were mailed a letter with an invitation to the online survey and a unique code. Given the mailed nature of the study, written or verbal consent was not obtained. Consent was implied with completion of the study; and it was emphasized in the invitation letter that a) participation was voluntary; b) participation was confidential; c) they could quit the study at any time without penalty; d) decisions not to participate would not affect their status as a patient at the participating institution; and e) all results would be presented in aggregate and no individual identifiers would be used.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Data is available upon request.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}